Find a Phase 1 clinical trial

The table below shows a list of the Experimental Cancer Medicine Team's currently recruiting phase I clinical trials. The arrow links will guide you to clinicaltrials.gov. This is an external public domain database showing clinical trials from around the world.

If you are a patient and you are interested in taking part in a clinical trial listed below, please talk to your oncologist or doctor about the trial you are interested in. We cannot accept nor respond to direct patient requests to participate on a clinical trial. If you are a patient you must be referred to us from your treating physician.

Oncologists working at external sites should contact centralregistration@christie.nhs.uk

If you are an Oncologist from within The Christie you are able to use this referral form to refer patients.

 

Target mechanism of investigative drug

 

Title of clinical trial

 

Hyperlink

 

DARWIN 1

 

Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

 

Contact ECMT enquiries

 

DARWIN 2

 

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II) - A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis

 

Contact ECMT enquiries

 

INC2108

 

A multicenter, open label, phase 1 dose escalation study to evaluate the pharmacokinetics, safety, and tolerability of INC280 tablet formulation with food in patients with CMet dysregulated advanced solid tumors

 

 

 

HuMax®-AXL-ADC

 

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax®-AXL-ADC) in patients with solid tumors

 

 

 

anti-PD-L1 / TGFβ-Trap molecule

 

A Phase 1, open label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetcs, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumours and expansion to selected indications

 

 

 

Anti-PDL-1

 

An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in patients with Muscle Invasive Bladder Cancer (MIBC) who have progressed on prior treatment (BISCAY)

 

 

 

oral pan-RAF inhibitor in comb. with paclitaxel

 

A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients With Advanced Nonhematologic Malignancies

 

 

 

oral HSP90 inhibitor

 

A Phase I Study Evaluating TAS-116 in Patients With Advanced Solid Tumors

 

 

alpha folate receptor targeted TS inhibitor

 

A Phase I trial of ONX-0801 (a novel α-folate receptor-mediated thymidylate synthase inhibitor) exploring once weekly and alternate week dosing regimens in patients with solid tumours

 

 

 

ATM kinase inhibitor

 

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (AToM)

 

 

 

 

PTEN-deficient/Mutated or PIK3CB Mutated Advanced Solid Malignancies

 

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186

 

 

 

 

Non-CTIMP

 

Tumour Characterisation to Guide Experimental Targeted Therapy

 

 

Contact ECMT enquiries

 

PanRaf Inhibitor (CCT3833)

 

A Phase 1, First in Man, Dual Centre, Open-label Dose Escalation Study With Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CCT3833 (BAL3833), a panRAF Inhibitor, Given Orally in Patients With Advanced Solid Tumours, Including Metastatic Melanoma

 

 

 

ATR / PI3K inhibitor (AZD6738) in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents

 

A Modular Phase I, Open-Label, Multicentre Study
to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies

 

 

 

ATR Inhibitor (VX970) in combination with cytotoxic chemo

 

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination with Either Gemcitabine or Cisplatin and Etoposide in Subjects with Advanced Solid Tumors

 

 

 

ALK inhibitor

 

A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)

 

 

 

TAS3681

 

A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability, and Pharmacokinetic Study of TAS3681 in Patients with Metastatic Castration Resistant Prostate Cancer

 

 

 

PEN221

 

A Phase 1/2a, open-label multicenter study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEN-221 in patients with advanced gastroenteropancreatic or lung neuroendocrine tumors or advanced small-cell lung cancer or other advanced cancers expressing somatostatin receptor 2

 

 

 

PDR2102

 

A phase Ib, multi-center, open-label study of PDR001 in combination with LCL161, panobinostat or everolimus in patients with advanced/metastatic CRC, TNBC or NSCLC

 

 

 

PLEASE NOTE - These trials are updated every 2 weeks on a Wednesday.

;